Filter results

Clinical Studies


  • A Prospective Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer’s Disease Jacksonville, Fla.

    The purpose of this study is to characterize and study the relationship of the clinical risk factors and predictors of seizures and epilepsy in patients with Early Onset Alzheimer's Disease (EOAD) using a 48-hour CAA-EEG.

  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3) Jacksonville, Fla., Rochester, Minn.

    Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study) (A4) Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) (ALLFTD) Rochester, Minn., Jacksonville, Fla.

    The purpose of this study is to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design.  FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures.

    The study has two arms: a “longitudinal arm” involving a comprehensive assessment of clinical, functional, imaging, and biofluid data collection, and a “biofluid-focused arm” involving limited clinical data to accompany biospecimen collection.

  • Brain Health and Dementia Prevention Registry Jacksonville, Fla.

    The purpose of this study is to create a registry of patients having a clinical diagnosis and collect demographics, cognitive testing, blood and cerebrospinal fluid so that biomarkers and genetic difference can be found in different patient groups.

  • Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS) Jacksonville, Fla., Rochester, Minn.

    The purpose of this Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants.

  • Longitudinal Imaging Biomarkers of Disease Progression in DLB Jacksonville, Fla., Rochester, Minn.

    To determine the paths of change in imaging biomarkers of DLB and their associations with rate of cognitive and functional decline.

  • Mayo Alzheimer's Disease Research Center Jacksonville, Fla., Rochester, Minn.

    This study is being done to learn more about normal memory and aging, mild memory and thinking problems, Alzheimer's disease and other forms of dementia.

  • Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 Rochester, Minn.

    The primary objective is to evaluate the long-term safety and tolerability of aducanumab after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e., previously treated participants) or who had previously received placebo (i.e, treatment-naïve participants).

  • Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD) (TRC-PAD) Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (

Contact Us for the Latest Status

Closed for Enrollment